8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Apr 20, 2026·SEC
Material company update
Apr 16, 2026·SEC
Aspire Biopharma Holdings, Inc.(ASBP)Earnings, Financials & Key Ratios
ASBP•NASDAQ
Price updated Jun 19, 2026
AboutAspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.Show more
- Revenue$6K
- EBITDA-$19M-66.2%
- Net Income-$24M-95.3%
- EPS (Diluted)-16.38+9.9%
- Gross Margin-1.87%
- EBITDA Margin-312016.95%
- Operating Margin-312016.95%
- Net Margin-394725.06%
ASBP Key Insights
Aspire Biopharma Holdings, Inc. (ASBP) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ASBP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ASBP Price & Volume
Aspire Biopharma Holdings, Inc. (ASBP) stock price & volume — 10-year historical chart
Loading chart...
ASBP Growth Metrics
Aspire Biopharma Holdings, Inc. (ASBP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM54.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM73.23%
Return on Capital
10 Years-11.91%
5 Years-11.91%
3 Years-17.54%
Last Year-
ASBP Recent Earnings
Aspire Biopharma Holdings, Inc. (ASBP) EPS & revenue vs analyst estimates — last 4 quarters
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$20.57
—
Rev
$28,353
—
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$3.15
—
Rev
$4,261
—
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.04
—
Rev
$1,941
—
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.04
—
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $20.57 | $28,353 |
| Q2 2026 | Mar 30, 2026 | $3.15 | $4,261 |
| Q4 2025 | Nov 14, 2025 | $0.04 | $1,941 |
| Q3 2025 | Aug 13, 2025 | $0.04 | — |
Based on last 12 quarters of dataView full earnings history →
ASBP Peer Comparison
Aspire Biopharma Holdings, Inc. (ASBP) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRBP | 103.54M | 8.26 | -1.40 | -70.89% | 0.01 | |||
 YCBD | 7.56M | 0.72 | -0.66 | -1.5% | -13.29% | -33.59% | 107.70 | |
 XXII | 1.6M | 4.65 | -0.09 | -40.66% | -44.9% | -25.03% | 0.27 | |
 ATAI | 1.49B | 4.06 | -1.40 | 12.28% | -190.19% | -366.21% | 0.01 | |
 CMPS | 1.2B | 12.53 | -4.07 | -151.02% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -102.48% | ||||
 CRON | 1.01B | 2.71 | -110.61 | 64.4% | -0.98% | -0.18% | 0.00 | |
 CGC | 372.36M | 0.97 | -1.55 | 79.81% | -117.39% | -49.5% | 0.33 |
Compare ASBP vs Peers
Aspire Biopharma Holdings, Inc. (ASBP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ASBP Income Statement
Aspire Biopharma Holdings, Inc. (ASBP) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 6.2K | 34.55K |
Revenue Growth % | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 6.32K | 28.92K |
COGS % of Revenue | - | - | - | - | 101.87% | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -116▲ 0% | 5.63K▲ 0% |
Gross Margin % | - | - | - | - | -1.87% | 16.3% |
Gross Profit Growth % | - | - | - | - | - | - |
Operating Expenses | 25.48K | 976.35K | 1.34M | 3.09M | 19.35M | 5.45M |
OpEx % of Revenue | - | - | - | - | 312015.08% | - |
Selling, General & Admin | 27.79K | 976.35K | 1.34M | 3.09M | 18.43M | 4.49M |
SG&A % of Revenue | - | - | - | - | 297118.04% | - |
Research & Development | 0 | 175.32K | 72.05K | 144.36K | 923.91K | 957.54K |
R&D % of Revenue | - | - | - | - | 14897.03% | - |
Other Operating Expenses | -2.32K | -175.32K | -72.05K | -144.36K | 0 | 0 |
Operating Income | -25.48K▲ 0% | -976.35K▼ 3731.8% | -1.34M▼ 37.2% | -3.09M▼ 130.5% | -19.35M▼ 526.5% | -5.44M▲ 0% |
Operating Margin % | - | - | - | - | -312016.95% | -15745.85% |
Operating Income Growth % | - | -3731.81% | -37.25% | -130.5% | -526.52% | - |
EBITDA | 2.31K | 3.34M | 0 | -11.65M | -19.35M | -4.07M |
EBITDA Margin % | - | - | - | - | -312016.95% | -11787.82% |
EBITDA Growth % | - | 144436.48% | -100% | - | -66.16% | 83.91% |
D&A (Non-Cash Add-back) | 27.79K | 0 | 1.34M | 0 | 0 | 2.02M |
EBIT | 0 | 3.34M | 4.47M | -11.65M | -19.35M | -5.32M |
Net Interest Income | 0 | 4.32M | 5.8M | -342.95K | -8.53M | -9.83M |
Interest Income | 0 | 4.32M | 5.81M | 548.68K | 0 | 5.01K |
Interest Expense | 0 | 0 | 8.97K | -892K | 8.53M | 9.84M |
Other Income/Expense | 5 | 4.32M | 5.8M | -9.45M | -5.13M | -6.32M |
Pretax Income | -25.48K▲ 0% | 3.34M▲ 13210.9% | 4.46M▲ 33.7% | -12.54M▼ 380.8% | -24.48M▼ 95.3% | -11.76M▲ 0% |
Pretax Margin % | - | - | - | - | -394725.06% | -34039.68% |
Income Tax | 0 | 626 | 0 | 1.01K | 0 | 0 |
Effective Tax Rate % | 0% | 0.02% | 0% | -0.01% | 0% | 0% |
Net Income | -25.48K▲ 0% | 3.34M▲ 13210.9% | 4.46M▲ 33.7% | -12.54M▼ 380.8% | -24.48M▼ 95.3% | -11.76M▲ 0% |
Net Margin % | - | - | - | - | -394725.06% | -34039.68% |
Net Income Growth % | - | 13210.89% | 33.65% | -380.85% | -95.27% | 54.78% |
Net Income (Continuing) | -25.48K | 3.34M | 4.46M | -12.54M | -24.48M | -11.76M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.04▲ 0% | 3.72▲ 10073.2% | 9.31▲ 150.3% | -18.17▼ 295.2% | -16.38▲ 9.9% | -7.87▲ 0% |
EPS Growth % | - | 10073.19% | 150.27% | -295.17% | 9.85% | 73.23% |
EPS (Basic) | -0.04 | 3.72 | 9.31 | -18.17 | -16.38 | - |
Diluted Shares Outstanding | 682.81K | 898.44K | 479.48K | 689.91K | 1.49M | 1.49M |
Basic Shares Outstanding | 682.81K | 898.44K | 479.48K | 689.91K | 1.49M | 1.49M |
Dividend Payout Ratio | - | - | - | - | - | - |
ASBP Balance Sheet
Aspire Biopharma Holdings, Inc. (ASBP) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 293.22K | 1.1M | 81.22K | 147.99K | 1.31M | 7.12M |
Cash & Short-Term Investments | 0 | 497.26K | 11.17K | 3.63K | 1M | 5.86M |
Cash Only | 0 | 497.26K | 0 | 3.63K | 1M | 5.86M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 36.5K | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 253.16K | 369.97K |
Days Inventory Outstanding | - | - | - | - | 14.63K | 2.08K |
Other Current Assets | 293.22K | 600.49K | 70.05K | 107.85K | 55.1K | 890.15K |
Total Non-Current Assets | 293.22K | 299.08M | 19.9M | 6.67M | 0 | 0 |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 299K | 19.9M | 6.67M | 0 | 0 |
Other Non-Current Assets | 293.22K | 298.79M | 0 | 0 | 0 | 0 |
Total Assets | 293.22K▲ 0% | 300.18M▲ 102274.0% | 19.98M▼ 93.3% | 147.99K▼ 99.3% | 1.31M▲ 786.7% | 7.12M▲ 0% |
Asset Turnover | - | - | - | - | 0.00x | 0.01x |
Asset Growth % | - | 102273.98% | -93.34% | -99.26% | 786.66% | 899.24% |
Total Current Liabilities | 293.7K | 303.32K | 403.33K | 1.69M | 7.59M | 3.15M |
Accounts Payable | 273 | 180.63K | 152K | 310.22K | 1.01M | 857.92K |
Days Payables Outstanding | - | - | - | - | 58.6K | 13.52K |
Short-Term Debt | 238.6K | 27.97K | 12.38K | 1.27M | 1.38M | 499.21K |
Deferred Revenue (Current) | 0 | 80 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | -28.05K | 0 | 111.03K | 4.84M | 1.8M |
Current Ratio | 1.00x | 3.62x | 0.20x | 0.09x | 0.17x | 2.26x |
Quick Ratio | 1.00x | 3.62x | 0.20x | 0.09x | 0.14x | 2.14x |
Cash Conversion Cycle | - | - | - | - | - | -11.44K |
Total Non-Current Liabilities | 0 | 10.81M | 0 | 0 | 95.66K | 96.25K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 10.81M | 0 | 0 | 95.66K | 96.25K |
Total Liabilities | 293.7K | 11.12M | 403.33K | 1.69M | 7.69M | 3.25M |
Total Debt | 238.6K | 27.97K | 12.38K | 1.27M | 1.38M | 499.21K |
Net Debt | 238.6K | -497.26K | 12.38K | 1.26M | 380.87K | -5.36M |
Debt / Equity | - | 0.00x | 0.00x | - | - | 0.13x |
Debt / EBITDA | 103.24x | 0.01x | - | - | - | -0.12x |
Net Debt / EBITDA | 103.24x | -0.15x | - | - | - | 1.32x |
Interest Coverage | - | - | 498.88x | -13.06x | -2.27x | -0.54x |
Total Equity | -475▲ 0% | 289.07M▲ 60856138.3% | 19.58M▼ 93.2% | -1.54M▼ 107.9% | -6.38M▼ 314.0% | 3.87M▲ 0% |
Equity Growth % | - | 60856138.32% | -93.23% | -107.87% | -314.02% | -14592.62% |
Book Value per Share | -0.00 | 321.74 | 40.83 | -2.23 | -4.27 | 2.59 |
Total Shareholders' Equity | -475 | 289.07M | 19.58M | -1.54M | -6.38M | 3.87M |
Common Stock | 718 | 299M | 19.9M | 169.99K | 353 | 17 |
Retained Earnings | -25.48K | -9.94M | -11.29M | -2.78M | -27.26M | -30.48M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
ASBP Cash Flow Statement
Aspire Biopharma Holdings, Inc. (ASBP) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | -260 | -1.41M | -653.11K | -265.19K | -4.92M | -6.21M |
Operating CF Margin % | - | - | - | - | -79385.49% | - |
Operating CF Growth % | - | -541740.77% | 53.64% | 59.4% | -1756.62% | -166.4% |
Net Income | -28 | 3.34M | 4.46M | -1.31M | -24.48M | -11.76M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 8.02M | 9.6M |
Stock-Based Compensation | 0 | 0 | 0 | 0 | 14.13M | 13.41K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | -4.32M | -5.8M | 10.7K | -3.13M | -2.98M |
Working Capital Changes | -232 | -432.44K | 687.06K | 1.03M | 533.38K | -1.08M |
Change in Receivables | 0 | 0 | 0 | -36.5K | 0 | 1.03M |
Change in Inventory | 0 | 0 | 0 | 0 | -253.16K | -369.97K |
Change in Payables | 0 | 125.53K | -28.63K | 0 | -323.78K | -1.59M |
Cash from Investing | 0 | -294.69M | 284.92M | 0 | 0 | 0 |
Capital Expenditures | 0 | -4.9M | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 0 | -289.79M | 284.92M | -13.78M | 0 | 0 |
Cash from Financing | 260 | 296.59M | -284.76M | 257.64K | 5.92M | 10.72M |
Debt Issued (Net) | 0 | -252.91K | 155.85K | 1.71M | 6.57M | -3.98M |
Equity Issued (Net) | 0 | 297.14M | -284.76M | -13.44M | 265.83K | 8.69M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -284.92M | -13.78M | 0 | 0 |
Other Financing | 260 | -298.54K | -155.85K | 11.98M | -907.5K | 6.02M |
Net Change in Cash | 0▲ 0% | 497.26K▲ 0% | -497.26K▼ 200.0% | -7.54K▲ 98.5% | 1M▲ 13364.4% | 4.51M▲ 0% |
Free Cash Flow | -260▲ 0% | -1.41M▼ 541740.8% | -653.11K▲ 53.6% | -265.19K▲ 59.4% | -4.92M▼ 1756.6% | -6.21M▲ 0% |
FCF Margin % | - | - | - | - | -79385.49% | -17972.74% |
FCF Growth % | - | -541740.77% | 53.64% | 59.4% | -1756.62% | -2652.88% |
FCF per Share | -0.00 | -1.57 | -1.36 | -0.38 | -3.29 | -4.15 |
FCF Conversion (FCF/Net Income) | 0.01x | -0.42x | -0.15x | 0.02x | 0.20x | 0.53x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
ASBP Key Ratios
Aspire Biopharma Holdings, Inc. (ASBP) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
Return on Equity (ROE) | 2.31% | 2.89% | -139% | - | 199.43% |
Return on Invested Capital (ROIC) | -0.51% | -0.65% | -23.99% | - | 59.34% |
Gross Margin | - | - | - | -1.87% | 16.3% |
Net Margin | - | - | - | -394725.06% | -34039.68% |
Debt / Equity | 0.00x | 0.00x | - | - | 0.13x |
Interest Coverage | - | 498.88x | -13.06x | -2.27x | -0.54x |
FCF Conversion | -0.42x | -0.15x | 0.02x | 0.20x | 0.53x |
Related:ASBP Dividend History·ASBP Revenue History·ASBP Price History·ASBP P/E History·ASBP Financial Ratios·ASBP Institutional Holders
ASBP SEC Filings & Documents
Aspire Biopharma Holdings, Inc. (ASBP) SEC filings — annual & quarterly reports (10-K, 10-Q)
ASBP Frequently Asked Questions
Aspire Biopharma Holdings, Inc. (ASBP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aspire Biopharma Holdings, Inc. (ASBP) reported $0.0M in revenue for fiscal year 2025.
Aspire Biopharma Holdings, Inc. (ASBP) grew revenue by 0.0% over the past year. Growth has been modest.
Aspire Biopharma Holdings, Inc. (ASBP) reported a net loss of $11.8M for fiscal year 2025.
Dividend & Returns
Aspire Biopharma Holdings, Inc. (ASBP) had negative free cash flow of $6.2M in fiscal year 2025, likely due to heavy capital investments.